Debashis Ghosh
Concepts (853)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1782 | 4.870 |
Why?
| | Leishmaniasis, Visceral | 18 | 2026 | 24 | 4.710 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 372 | 4.390 |
Why?
| | Models, Statistical | 44 | 2024 | 681 | 4.310 |
Why?
| | Algorithms | 41 | 2025 | 1837 | 3.960 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 758 | 3.270 |
Why?
| | Computational Biology | 21 | 2025 | 680 | 2.620 |
Why?
| | Computer Simulation | 36 | 2024 | 1025 | 2.530 |
Why?
| | Machine Learning | 10 | 2024 | 585 | 2.450 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.150 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1313 | 2.120 |
Why?
| | Metabolomics | 9 | 2022 | 727 | 2.060 |
Why?
| | Biometry | 13 | 2011 | 68 | 2.030 |
Why?
| | Software | 16 | 2025 | 690 | 2.000 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 974 | 1.810 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 17 | 1.700 |
Why?
| | Eye Proteins | 6 | 2016 | 90 | 1.640 |
Why?
| | Neoplasms | 25 | 2024 | 2875 | 1.580 |
Why?
| | Regression Analysis | 13 | 2021 | 1003 | 1.410 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.400 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.390 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 920 | 1.300 |
Why?
| | Genomics | 12 | 2024 | 834 | 1.280 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 442 | 1.270 |
Why?
| | Models, Biological | 14 | 2021 | 1821 | 1.220 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1455 | 1.210 |
Why?
| | Proportional Hazards Models | 11 | 2023 | 1325 | 1.200 |
Why?
| | Humans | 203 | 2026 | 144759 | 1.200 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 427 | 1.100 |
Why?
| | Causality | 4 | 2022 | 126 | 1.090 |
Why?
| | Biomarkers | 14 | 2021 | 4271 | 1.090 |
Why?
| | Bangladesh | 15 | 2026 | 62 | 1.080 |
Why?
| | Databases, Factual | 12 | 2024 | 1486 | 1.070 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 338 | 1.070 |
Why?
| | Insecticides | 4 | 2023 | 42 | 1.040 |
Why?
| | Biostatistics | 3 | 2014 | 19 | 1.020 |
Why?
| | Insect Control | 4 | 2023 | 18 | 1.020 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2024 | 780 | 1.020 |
Why?
| | Insect Vectors | 4 | 2023 | 39 | 1.020 |
Why?
| | Aromatase | 2 | 2019 | 32 | 0.970 |
Why?
| | Endemic Diseases | 2 | 2024 | 33 | 0.960 |
Why?
| | Survival Analysis | 12 | 2024 | 1382 | 0.950 |
Why?
| | Natural Gas | 1 | 2025 | 26 | 0.880 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 174 | 0.880 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 33 | 0.880 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 293 | 0.870 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 732 | 0.850 |
Why?
| | Microscopy | 3 | 2023 | 156 | 0.840 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2637 | 0.820 |
Why?
| | Magnetoencephalography | 2 | 2021 | 160 | 0.820 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.820 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 259 | 0.810 |
Why?
| | Histological Techniques | 1 | 2023 | 38 | 0.800 |
Why?
| | Environmental Exposure | 3 | 2025 | 588 | 0.780 |
Why?
| | Genetic Association Studies | 5 | 2019 | 372 | 0.760 |
Why?
| | Models, Genetic | 11 | 2019 | 536 | 0.760 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1539 | 0.760 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 442 | 0.750 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 311 | 0.740 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.710 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 358 | 0.710 |
Why?
| | Connectome | 2 | 2021 | 95 | 0.700 |
Why?
| | Mass Spectrometry | 6 | 2022 | 750 | 0.690 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 461 | 0.680 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 43 | 0.680 |
Why?
| | Brain Mapping | 2 | 2021 | 536 | 0.670 |
Why?
| | Housing | 2 | 2021 | 144 | 0.660 |
Why?
| | Phenotype | 13 | 2026 | 3162 | 0.660 |
Why?
| | Brain | 4 | 2024 | 2933 | 0.660 |
Why?
| | Endpoint Determination | 2 | 2011 | 83 | 0.650 |
Why?
| | Cluster Analysis | 12 | 2024 | 521 | 0.640 |
Why?
| | Nitriles | 1 | 2021 | 205 | 0.640 |
Why?
| | Propensity Score | 4 | 2018 | 367 | 0.630 |
Why?
| | Feasibility Studies | 2 | 2024 | 1095 | 0.620 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1053 | 0.610 |
Why?
| | Placenta | 2 | 2019 | 780 | 0.600 |
Why?
| | Risk Assessment | 8 | 2020 | 3671 | 0.600 |
Why?
| | Databases, Genetic | 11 | 2021 | 248 | 0.590 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 175 | 0.590 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 121 | 0.590 |
Why?
| | Learning | 1 | 2023 | 452 | 0.590 |
Why?
| | Genetic Variation | 4 | 2019 | 983 | 0.590 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 118 | 0.580 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 183 | 0.580 |
Why?
| | Metadata | 1 | 2018 | 17 | 0.570 |
Why?
| | Metabolome | 1 | 2021 | 384 | 0.540 |
Why?
| | Protein Conformation | 4 | 2015 | 946 | 0.540 |
Why?
| | Logistic Models | 12 | 2020 | 2117 | 0.530 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2168 | 0.530 |
Why?
| | Male | 78 | 2026 | 72315 | 0.530 |
Why?
| | Glioma | 1 | 2022 | 425 | 0.530 |
Why?
| | Transcriptome | 2 | 2023 | 1045 | 0.520 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3409 | 0.520 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 89 | 0.510 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1720 | 0.510 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1716 | 0.500 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1180 | 0.490 |
Why?
| | Markov Chains | 7 | 2017 | 129 | 0.460 |
Why?
| | High-Intensity Interval Training | 2 | 2026 | 46 | 0.460 |
Why?
| | Female | 64 | 2026 | 78271 | 0.460 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1985 | 0.460 |
Why?
| | Linear Models | 7 | 2018 | 854 | 0.460 |
Why?
| | Registries | 2 | 2024 | 2385 | 0.450 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 162 | 0.450 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 492 | 0.440 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.430 |
Why?
| | HIV Infections | 7 | 2026 | 3154 | 0.430 |
Why?
| | Protein Folding | 1 | 2016 | 279 | 0.430 |
Why?
| | Case-Control Studies | 10 | 2025 | 3604 | 0.430 |
Why?
| | Bayes Theorem | 7 | 2022 | 433 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 641 | 0.420 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 91 | 0.420 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 412 | 0.420 |
Why?
| | Lupus Nephritis | 2 | 2025 | 70 | 0.410 |
Why?
| | Statistics as Topic | 3 | 2025 | 284 | 0.410 |
Why?
| | Nerve Net | 3 | 2024 | 285 | 0.410 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 112 | 0.400 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1406 | 0.390 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 167 | 0.390 |
Why?
| | Treatment Outcome | 10 | 2026 | 11679 | 0.390 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 168 | 0.390 |
Why?
| | Bias | 5 | 2022 | 202 | 0.380 |
Why?
| | India | 6 | 2023 | 218 | 0.380 |
Why?
| | Disease Progression | 15 | 2021 | 2847 | 0.370 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 50 | 0.370 |
Why?
| | Oncogenes | 1 | 2013 | 119 | 0.360 |
Why?
| | Herpes Zoster Vaccine | 2 | 2025 | 154 | 0.350 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.350 |
Why?
| | Animals | 33 | 2025 | 38058 | 0.350 |
Why?
| | Exercise Therapy | 2 | 2026 | 473 | 0.340 |
Why?
| | Genome | 5 | 2017 | 306 | 0.340 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 7 | 0.340 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 592 | 0.340 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 560 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2583 | 0.330 |
Why?
| | Middle Aged | 38 | 2026 | 35875 | 0.330 |
Why?
| | Aged | 32 | 2026 | 25913 | 0.330 |
Why?
| | Monocytes | 2 | 2025 | 538 | 0.320 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 23 | 0.320 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2145 | 0.320 |
Why?
| | Herpes Zoster | 2 | 2025 | 315 | 0.320 |
Why?
| | Alzheimer Disease | 3 | 2015 | 621 | 0.320 |
Why?
| | Precision Medicine | 2 | 2025 | 457 | 0.320 |
Why?
| | Adenocarcinoma | 4 | 2017 | 928 | 0.320 |
Why?
| | Principal Component Analysis | 2 | 2023 | 197 | 0.320 |
Why?
| | Antioxidants | 1 | 2014 | 549 | 0.310 |
Why?
| | Models, Neurological | 2 | 2024 | 254 | 0.310 |
Why?
| | Child, Preschool | 9 | 2025 | 11787 | 0.310 |
Why?
| | Gene Expression | 3 | 2014 | 1490 | 0.310 |
Why?
| | Colorado | 6 | 2025 | 4564 | 0.310 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 266 | 0.300 |
Why?
| | Stem Cells | 3 | 2020 | 626 | 0.300 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 117 | 0.300 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 29 | 0.300 |
Why?
| | Gene Dosage | 1 | 2010 | 148 | 0.300 |
Why?
| | Signal Transduction | 10 | 2025 | 5226 | 0.300 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 139 | 0.290 |
Why?
| | Risk Factors | 14 | 2025 | 10779 | 0.290 |
Why?
| | Child | 16 | 2025 | 22633 | 0.280 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 294 | 0.280 |
Why?
| | Protein Array Analysis | 8 | 2009 | 56 | 0.280 |
Why?
| | Carcinoma | 2 | 2007 | 228 | 0.280 |
Why?
| | Liver Neoplasms | 1 | 2015 | 780 | 0.280 |
Why?
| | Proteomics | 5 | 2009 | 1195 | 0.280 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.280 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.270 |
Why?
| | Probability | 3 | 2021 | 310 | 0.270 |
Why?
| | Chromosome Mapping | 6 | 2017 | 510 | 0.270 |
Why?
| | Emigration and Immigration | 1 | 2008 | 66 | 0.270 |
Why?
| | Exercise | 3 | 2026 | 2201 | 0.270 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1499 | 0.260 |
Why?
| | DNA Methylation | 4 | 2023 | 681 | 0.260 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 361 | 0.260 |
Why?
| | Research Design | 5 | 2021 | 1135 | 0.260 |
Why?
| | Flow Cytometry | 2 | 2022 | 1173 | 0.250 |
Why?
| | Adult | 28 | 2026 | 40449 | 0.250 |
Why?
| | Tumor Burden | 1 | 2008 | 319 | 0.250 |
Why?
| | Disease Eradication | 1 | 2026 | 5 | 0.240 |
Why?
| | Entropy | 2 | 2023 | 45 | 0.240 |
Why?
| | Proteome | 3 | 2007 | 518 | 0.240 |
Why?
| | Pancreas | 2 | 2020 | 341 | 0.240 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 255 | 0.240 |
Why?
| | Monte Carlo Method | 4 | 2017 | 155 | 0.230 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1098 | 0.230 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 215 | 0.230 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 24 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2021 | 2496 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 549 | 0.220 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1462 | 0.220 |
Why?
| | False Positive Reactions | 4 | 2012 | 121 | 0.220 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2155 | 0.220 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 108 | 0.220 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 523 | 0.220 |
Why?
| | Sarcopenia | 1 | 2026 | 91 | 0.220 |
Why?
| | Adolescent | 13 | 2026 | 22428 | 0.220 |
Why?
| | Cell Nucleus | 2 | 2019 | 618 | 0.220 |
Why?
| | Replication Origin | 1 | 2004 | 21 | 0.220 |
Why?
| | Herpesvirus 3, Human | 2 | 2025 | 336 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 178 | 0.210 |
Why?
| | Coinfection | 1 | 2026 | 141 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2363 | 0.210 |
Why?
| | Fever | 2 | 2023 | 311 | 0.210 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 67 | 0.210 |
Why?
| | Weather | 1 | 2024 | 43 | 0.210 |
Why?
| | Dengue Virus | 1 | 2024 | 58 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3863 | 0.210 |
Why?
| | Data Curation | 1 | 2024 | 21 | 0.200 |
Why?
| | Leukemia | 1 | 2006 | 245 | 0.200 |
Why?
| | Carrier Proteins | 2 | 2007 | 737 | 0.200 |
Why?
| | Antigens | 1 | 2005 | 347 | 0.200 |
Why?
| | Melanoma | 3 | 2005 | 761 | 0.200 |
Why?
| | Ligands | 2 | 2016 | 673 | 0.200 |
Why?
| | ROC Curve | 5 | 2020 | 614 | 0.200 |
Why?
| | Dengue | 1 | 2024 | 89 | 0.200 |
Why?
| | Cell Phone | 1 | 2024 | 82 | 0.200 |
Why?
| | Sample Size | 3 | 2008 | 123 | 0.200 |
Why?
| | Coculture Techniques | 1 | 2004 | 246 | 0.200 |
Why?
| | Histones | 4 | 2020 | 669 | 0.190 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 26 | 0.190 |
Why?
| | Staining and Labeling | 1 | 2023 | 151 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1137 | 0.190 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.190 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 154 | 0.190 |
Why?
| | Recurrence | 5 | 2023 | 1135 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 479 | 0.190 |
Why?
| | Carcinogens | 1 | 2003 | 122 | 0.190 |
Why?
| | Frailty | 1 | 2026 | 198 | 0.190 |
Why?
| | Organometallic Compounds | 1 | 2023 | 112 | 0.190 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 173 | 0.190 |
Why?
| | Young Adult | 12 | 2026 | 14105 | 0.190 |
Why?
| | Emphysema | 1 | 2023 | 100 | 0.190 |
Why?
| | Personality | 1 | 2004 | 132 | 0.190 |
Why?
| | DNA, Complementary | 4 | 2007 | 276 | 0.180 |
Why?
| | Biomedical Research | 2 | 2025 | 710 | 0.180 |
Why?
| | Retina | 2 | 2016 | 324 | 0.180 |
Why?
| | Neuroimaging | 2 | 2015 | 289 | 0.180 |
Why?
| | Parasites | 1 | 2022 | 44 | 0.180 |
Why?
| | Body Composition | 1 | 2026 | 706 | 0.180 |
Why?
| | Estrogens | 2 | 2019 | 380 | 0.180 |
Why?
| | Social Stigma | 1 | 2024 | 171 | 0.180 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2452 | 0.180 |
Why?
| | Construction Materials | 1 | 2021 | 18 | 0.170 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1257 | 0.170 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 496 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2730 | 0.170 |
Why?
| | Brain Waves | 1 | 2021 | 45 | 0.170 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 612 | 0.170 |
Why?
| | Infant | 3 | 2024 | 10034 | 0.170 |
Why?
| | Analysis of Variance | 4 | 2024 | 1306 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 558 | 0.170 |
Why?
| | Zebrafish | 2 | 2016 | 528 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1501 | 0.170 |
Why?
| | Mutation, Missense | 2 | 2016 | 340 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 239 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 192 | 0.170 |
Why?
| | Receptors, Androgen | 2 | 2021 | 153 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1833 | 0.170 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 61 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 373 | 0.160 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 102 | 0.160 |
Why?
| | Epilepsy | 2 | 2021 | 376 | 0.160 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 224 | 0.160 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 275 | 0.160 |
Why?
| | Peptides | 4 | 2007 | 995 | 0.160 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 74 | 0.160 |
Why?
| | Lymphocytes | 2 | 2023 | 382 | 0.160 |
Why?
| | RNA, Messenger | 8 | 2024 | 2832 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 114 | 0.150 |
Why?
| | Radiography | 1 | 2022 | 844 | 0.150 |
Why?
| | Androgens | 3 | 2012 | 186 | 0.150 |
Why?
| | Exome | 2 | 2018 | 227 | 0.150 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 124 | 0.150 |
Why?
| | Phosphorylation | 3 | 2019 | 1732 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 194 | 0.150 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5868 | 0.150 |
Why?
| | Disease Reservoirs | 1 | 2019 | 25 | 0.150 |
Why?
| | Tretinoin | 1 | 2020 | 124 | 0.150 |
Why?
| | Protein Binding | 5 | 2019 | 2273 | 0.150 |
Why?
| | Hospital Mortality | 1 | 2024 | 1030 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 576 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 885 | 0.150 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 45 | 0.150 |
Why?
| | Disease | 1 | 2019 | 98 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 60 | 0.140 |
Why?
| | Bone Regeneration | 1 | 2019 | 28 | 0.140 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2930 | 0.140 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2608 | 0.140 |
Why?
| | Mice | 16 | 2025 | 18339 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 69 | 0.140 |
Why?
| | Prognosis | 11 | 2021 | 4282 | 0.140 |
Why?
| | Radiology Information Systems | 1 | 2018 | 35 | 0.140 |
Why?
| | Pituitary Gland | 2 | 2009 | 148 | 0.140 |
Why?
| | Precancerous Conditions | 1 | 2020 | 166 | 0.140 |
Why?
| | Artificial Intelligence | 3 | 2008 | 365 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 100 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 862 | 0.140 |
Why?
| | Pilot Projects | 2 | 2021 | 1886 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 331 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 67 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 484 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 111 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 85 | 0.140 |
Why?
| | Nuclear Proteins | 2 | 2019 | 748 | 0.140 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2024 | 104 | 0.140 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 129 | 0.130 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 41 | 0.130 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 919 | 0.130 |
Why?
| | Intensive Care Units | 1 | 2024 | 916 | 0.130 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 86 | 0.130 |
Why?
| | CD24 Antigen | 1 | 2017 | 18 | 0.130 |
Why?
| | Time Factors | 6 | 2026 | 7173 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 635 | 0.130 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 25 | 0.130 |
Why?
| | Pregnancy | 5 | 2019 | 7190 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.130 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 163 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 157 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 114 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 117 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 208 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 688 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 161 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 851 | 0.120 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.120 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 181 | 0.120 |
Why?
| | Calcium Compounds | 1 | 2016 | 6 | 0.120 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 44 | 0.120 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 87 | 0.120 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 285 | 0.120 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1496 | 0.120 |
Why?
| | RNA, Viral | 2 | 2024 | 688 | 0.120 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 5 | 0.120 |
Why?
| | Normal Distribution | 2 | 2014 | 22 | 0.120 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 7 | 0.120 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 162 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2019 | 271 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 167 | 0.120 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 919 | 0.120 |
Why?
| | Mosquito Control | 1 | 2016 | 29 | 0.120 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 39 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 660 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 502 | 0.120 |
Why?
| | Anus Neoplasms | 1 | 2016 | 32 | 0.120 |
Why?
| | Transcription Factors | 6 | 2017 | 1741 | 0.120 |
Why?
| | ErbB Receptors | 2 | 2012 | 627 | 0.120 |
Why?
| | Oxides | 1 | 2016 | 51 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 396 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 459 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 105 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 582 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 383 | 0.120 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 32 | 0.120 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 30 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 82 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 103 | 0.120 |
Why?
| | Age Factors | 4 | 2026 | 3333 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 371 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 965 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 241 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 102 | 0.120 |
Why?
| | Heart Arrest | 1 | 2020 | 407 | 0.120 |
Why?
| | Cough | 2 | 2007 | 124 | 0.120 |
Why?
| | Berylliosis | 1 | 2018 | 202 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 388 | 0.110 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 339 | 0.110 |
Why?
| | Oleic Acid | 1 | 2015 | 42 | 0.110 |
Why?
| | Anesthesiologists | 1 | 2016 | 67 | 0.110 |
Why?
| | Proteolysis | 1 | 2016 | 173 | 0.110 |
Why?
| | Aged, 80 and over | 13 | 2022 | 8265 | 0.110 |
Why?
| | Mutation | 2 | 2025 | 4089 | 0.110 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1387 | 0.110 |
Why?
| | Parkinson Disease | 1 | 2021 | 600 | 0.110 |
Why?
| | Prevalence | 3 | 2026 | 2834 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 446 | 0.110 |
Why?
| | Risk | 1 | 2017 | 911 | 0.110 |
Why?
| | Air Pollution | 2 | 2017 | 327 | 0.110 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 382 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 412 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 412 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 36 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 2050 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 845 | 0.110 |
Why?
| | Ants | 1 | 2014 | 27 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2327 | 0.100 |
Why?
| | Influenza Vaccines | 1 | 2019 | 529 | 0.100 |
Why?
| | Executive Function | 1 | 2019 | 461 | 0.100 |
Why?
| | Catalysis | 2 | 2012 | 322 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 771 | 0.100 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.100 |
Why?
| | Cancer Survivors | 1 | 2019 | 327 | 0.100 |
Why?
| | Sulfonic Acids | 1 | 2014 | 17 | 0.100 |
Why?
| | Treatment Failure | 1 | 2015 | 365 | 0.100 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 57 | 0.100 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 85 | 0.100 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 15 | 0.100 |
Why?
| | Chromatography, Gel | 1 | 2014 | 131 | 0.100 |
Why?
| | Benzothiazoles | 1 | 2014 | 40 | 0.100 |
Why?
| | Amphotericin B | 1 | 2013 | 37 | 0.100 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 82 | 0.100 |
Why?
| | Survival Rate | 4 | 2019 | 2089 | 0.100 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3540 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 235 | 0.100 |
Why?
| | Vaccines, Synthetic | 2 | 2025 | 138 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1075 | 0.100 |
Why?
| | Brain Diseases | 1 | 2015 | 152 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 145 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 550 | 0.100 |
Why?
| | Resistance Training | 2 | 2026 | 182 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 130 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 405 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 616 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5960 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5408 | 0.090 |
Why?
| | Estradiol | 2 | 2014 | 533 | 0.090 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2025 | 437 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 323 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 76 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1253 | 0.090 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2022 | 39 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 10 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 917 | 0.090 |
Why?
| | Silver | 1 | 2012 | 38 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 76 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 437 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 205 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 26 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 928 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 983 | 0.090 |
Why?
| | Motion | 1 | 2012 | 100 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1169 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 16 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 15 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2025 | 846 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1173 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Heme | 1 | 2012 | 89 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 96 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 12 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 94 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 9 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 701 | 0.080 |
Why?
| | Cattle | 1 | 2014 | 1000 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 341 | 0.080 |
Why?
| | Catalytic Domain | 1 | 2012 | 232 | 0.080 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 237 | 0.080 |
Why?
| | Lipid Bilayers | 1 | 2012 | 103 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 172 | 0.080 |
Why?
| | Chemokines | 1 | 2011 | 218 | 0.080 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 508 | 0.080 |
Why?
| | Lung | 2 | 2023 | 4109 | 0.080 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 893 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1114 | 0.080 |
Why?
| | Vaccination | 1 | 2019 | 1423 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 157 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 95 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1087 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1168 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 294 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 650 | 0.070 |
Why?
| | Activities of Daily Living | 2 | 2003 | 441 | 0.070 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.070 |
Why?
| | Autoimmunity | 2 | 2025 | 926 | 0.070 |
Why?
| | Decision Trees | 2 | 2020 | 81 | 0.070 |
Why?
| | CpG Islands | 2 | 2023 | 165 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2016 | 947 | 0.070 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.070 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 130 | 0.070 |
Why?
| | Peptide Library | 2 | 2007 | 95 | 0.070 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 54 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 199 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 112 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 12 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 17066 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 672 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 35 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 333 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 682 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 144 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 52 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1618 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 888 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 89 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1021 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 250 | 0.060 |
Why?
| | Leisure Activities | 1 | 2007 | 30 | 0.060 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 34 | 0.060 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 397 | 0.060 |
Why?
| | Genes, myc | 1 | 2007 | 50 | 0.060 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 190 | 0.060 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.060 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 333 | 0.060 |
Why?
| | Nails | 1 | 2007 | 13 | 0.060 |
Why?
| | Self Concept | 1 | 2009 | 253 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1356 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1326 | 0.060 |
Why?
| | Genome, Human | 4 | 2016 | 422 | 0.060 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 121 | 0.060 |
Why?
| | Nepal | 2 | 2016 | 32 | 0.060 |
Why?
| | Genome, Bacterial | 2 | 2006 | 155 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 76 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 59 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 342 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3890 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2430 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 45 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 128 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 66 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 67 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 570 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 22 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 32 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 151 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 628 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 37 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 37 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 51 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 374 | 0.060 |
Why?
| | Frail Elderly | 1 | 2026 | 134 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 169 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 52 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 208 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 276 | 0.060 |
Why?
| | United States | 7 | 2018 | 15966 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 104 | 0.050 |
Why?
| | Family Characteristics | 2 | 2016 | 197 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 396 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2025 | 97 | 0.050 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 61 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 364 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 1767 | 0.050 |
Why?
| | Mobile Health Units | 1 | 2024 | 20 | 0.050 |
Why?
| | Disease-Free Survival | 3 | 2017 | 769 | 0.050 |
Why?
| | Area Under Curve | 2 | 2020 | 330 | 0.050 |
Why?
| | Environmental Pollutants | 1 | 2007 | 167 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 369 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 246 | 0.050 |
Why?
| | Poisson Distribution | 1 | 2004 | 78 | 0.050 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 17 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1054 | 0.050 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 20 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2026 | 233 | 0.050 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.050 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 48 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 308 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 160 | 0.050 |
Why?
| | Culture Techniques | 1 | 2004 | 67 | 0.050 |
Why?
| | Lipids | 1 | 2009 | 710 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 370 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 15 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 514 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 62 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 377 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 62 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 271 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2438 | 0.050 |
Why?
| | Fatigue | 1 | 2026 | 366 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 134 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 214 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2023 | 112 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 905 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 181 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 43 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 322 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1694 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 133 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 471 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 73 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 627 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 67 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 284 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 82 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1511 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 131 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 174 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1519 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 139 | 0.050 |
Why?
| | Breast | 1 | 2003 | 158 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 851 | 0.050 |
Why?
| | Health Policy | 1 | 2026 | 400 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 10 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 38 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 134 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2026 | 1414 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 142 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 721 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 251 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 389 | 0.050 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 467 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 316 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 102 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 132 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2025 | 499 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 188 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2008 | 1166 | 0.040 |
Why?
| | Yeasts | 1 | 2002 | 52 | 0.040 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 33 | 0.040 |
Why?
| | Hospitalization | 2 | 2024 | 2433 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 166 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5992 | 0.040 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 45 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 302 | 0.040 |
Why?
| | Epithelial Cells | 2 | 2008 | 1125 | 0.040 |
Why?
| | Seasons | 1 | 2024 | 556 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 415 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 32 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 539 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2027 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Japan | 1 | 2021 | 143 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 514 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 478 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 212 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 408 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 172 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 42 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 51 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 26 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 272 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 32 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 573 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 893 | 0.040 |
Why?
| | Policy | 1 | 2021 | 146 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2026 | 6048 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 558 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 36 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 282 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 81 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 232 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 300 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 668 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 98 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 15 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 147 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 21 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 538 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 348 | 0.040 |
Why?
| | Skin | 2 | 2017 | 755 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 25 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 97 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1329 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 3185 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 784 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4557 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 448 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 224 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 532 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 278 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 876 | 0.030 |
Why?
| | Malaria | 1 | 2019 | 73 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.030 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 684 | 0.030 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 40 | 0.030 |
Why?
| | Autoantigens | 1 | 2020 | 429 | 0.030 |
Why?
| | Seizures | 1 | 2021 | 460 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 509 | 0.030 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 245 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 32 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 313 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 178 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1495 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3121 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 52 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 46 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 90 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 136 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 16 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 223 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 73 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 16 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 17 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 141 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 101 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 96 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 1034 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 68 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 158 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 161 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 824 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 98 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 56 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 520 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 421 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 304 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 744 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 291 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 200 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 166 | 0.030 |
Why?
| | Family | 1 | 2019 | 679 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 318 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5597 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 965 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 66 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1266 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 137 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 847 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 21 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 633 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 224 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1134 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 354 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 347 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 105 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 29 | 0.030 |
Why?
| | Demography | 1 | 2014 | 288 | 0.020 |
Why?
| | Methylation | 1 | 2014 | 242 | 0.020 |
Why?
| | North America | 1 | 2014 | 310 | 0.020 |
Why?
| | Hospitals, Rural | 1 | 2013 | 51 | 0.020 |
Why?
| | Organ Specificity | 1 | 2014 | 312 | 0.020 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 112 | 0.020 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 457 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 180 | 0.020 |
Why?
| | Species Specificity | 1 | 2014 | 574 | 0.020 |
Why?
| | Cell Line | 2 | 2009 | 2882 | 0.020 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 92 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2061 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 423 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 824 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 94 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 160 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 111 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 73 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2310 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 39 | 0.020 |
Why?
| | Methane | 1 | 2012 | 51 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 255 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 319 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 266 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7990 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 872 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 31 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 15 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 730 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 383 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1347 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1558 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2507 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1769 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 38 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 395 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 50 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 299 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 327 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 126 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 100 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2194 | 0.020 |
Why?
| | Genes | 1 | 2008 | 226 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 28 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 248 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 336 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 36 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 28 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 512 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 43 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1953 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 181 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 454 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 251 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 392 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 26 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 20 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 41 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 26 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 56 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1339 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 32 | 0.020 |
Why?
| | Television | 1 | 2007 | 72 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 33 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 995 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 91 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 271 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 232 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 138 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 108 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 187 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1129 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 88 | 0.010 |
Why?
| | Ear, Middle | 1 | 2006 | 85 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1217 | 0.010 |
Why?
| | Urban Health | 1 | 2006 | 96 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 985 | 0.010 |
Why?
| | Drug Design | 1 | 2007 | 173 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1370 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2009 | 527 | 0.010 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 71 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 62 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 82 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 50 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 59 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 380 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 41 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 94 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 43 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 56 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 42 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 363 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 427 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 205 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 151 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 356 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 101 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 256 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 29 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 17 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 83 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 609 | 0.010 |
Why?
| | Internet | 1 | 2007 | 699 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 86 | 0.010 |
Why?
| | California | 1 | 2003 | 475 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 596 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 183 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 222 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 541 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 623 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1658 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 940 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 955 | 0.010 |
Why?
| | RNA | 1 | 2005 | 940 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2115 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1256 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1966 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|